Cellular immune profile of patients with advanced cancer before and after taxane treatment

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 5, 2000, Pages 463-472

  Tong, A W ^b   Seamour, B ^b   Lawson, J M ^b   Ordonez, G ^b   Vukelja, S ^b   Hyman, W ^b   Richards, D ^b   Stein, L ^b   Maples, P B ^b   Nemunaitis, J ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b NONE

Author keywords

Cytokines; Natural killer cells; Ocetaxel; Paclitaxel

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; DOCETAXEL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; PACLITAXEL; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER THERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOPHENOTYPING; IMMUNOREGULATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOPHENOTYPING; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 0034443676     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200010000-00007     Document Type: Article

References (26)

1. Antimicrotubule agents
2. Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer
3. Monotherapy of metastatic breast cancer: A review of newer agents
4. Taxol-mediated changes in fibrosarcoma-induced immune cell function: Modulation of antitumor activities
5. Colchicine down-regulates lipopolysaccharide-induced granulocyte-macrophage colony-stimulating factor production in murine macrophages
6. Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T-lymphocytes, and breast cancer cells
7. Comparative studies of taxol and taxotere on tumor growth and lymphocyte functions
8. Taxol pretreatment of tumor targets amplifies natural killer cell mediated lysis
9. Augmentation of lymphokin-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma
10. Low-dose melphalan-induced up-regulation of type-I cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon-gamma in the therapeutic outcome
11. Importance of TNF production for the curative effectiveness of low-dose melphalan therapy for mice bearing a large MOPC-315 tumor
12. Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor β by treatment with bleomycin
13. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation
14. Tumor growth modulates macrophage nitric oxide production following paclitaxel administration
15. Overcoming suppression of anti-tumor immune reactivity in tumor-bearing rats by treatment with bleomycin
16. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma
17. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma
18. Expression of cytokine mRNA in human melanoma tissues
19. The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin-10 and differential changes in interferon gamma and interleukin 4 production
20. Interleukin-12 in early or advanced cancer patients
21. Use of cellular and cytokine adjuvant in the immunotherapy of cancer
22. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma
23. Vaccination with IL-12 gene modified autologous melanoma cells: Preclinical results and a first clinical phase I study
24. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy
25. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo
26. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies